| [1] |
Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine: "A White Paper, Community Perspective" [J]. Metabolomics, 2016, 12(10): 149.
|
| [2] |
Kalim S, Rhee EP. An overview of renal metabolomics [J]. Kidney Int, 2017, 91(1): 61-69.
|
| [3] |
Gathungu RM, Kautz R, Kristal BS, et al. The integration of LC-MS and NMR for the analysis of low molecular weight trace analytes in complex matrices [J]. Mass Spectrom Rev, 2018, [Epub ahead of print].
|
| [4] |
Alderson HV, Ritchie JP, Pagano S, et al. The associations of blood kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin with progression from CKD to ESRD [J]. Clin J Am Soc Nephrol, 2016, 11(12): 2141-2149.
|
| [5] |
Ichikawa D, Kamijo-Ikemori A, Sugaya T, et al. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion [J]. Nephrology (Carlton), 2018, 23(4): 308-316.
|
| [6] |
Goek ON, Prehn C, Sekula P, et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population [J]. Nephrol Dial Transplant, 2013, 28(8): 2131-2138.
|
| [7] |
Rhee EP, Clish CB, Ghorbani A, et al. A combined epidemiologic and metabolomic approach improves CKD prediction [J]. J Am Soc Nephrol, 2013, 24(8): 1330-1338.
|
| [8] |
Yu B, Zheng Y, Nettleton JA, et al. Serum metabolomic profiling and incident CKD among African Americans [J]. Clin J Am Soc Nephrol, 2014, 9(8): 1410-1417.
|
| [9] |
Rhee EP, Clish CB, Wenger J, et al. Metabolomics of chronic kidney disease progression: a case-control analysis in the chronic renal insufficiency cohort study [J]. Am J Nephrol, 2016, 43(5): 366-374.
|
| [10] |
Kobayashi T, Yoshida T, Fujisawa T, et al. A metabolomics-based approach for predicting stages of chronic kidney disease [J]. Biochem Biophys Res Commun, 2014, 445(2): 412-416.
|
| [11] |
Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease [J]. Nephrol Dial Transplant, 2011, 26(3): 938-947.
|
| [12] |
Cao XS, Chen J, Zou JZ, et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis [J]. Clin J Am Soc Nephrol, 2015, 10(1): 111-119.
|
| [13] |
Shafi T, Hostetter TH, Meyer TW, et al. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients [J]. Am J Kidney Dis, 2017, 70(1): 48-58.
|
| [14] |
Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study [J]. Lancet, 2001, 358(9299): 2113-2117.
|
| [15] |
Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study [J]. J Am Soc Nephrol, 2005, 16(8): 2456-2461.
|
| [16] |
Emrich IE, Zawada AM, Martens-Lobenhoffer J, et al. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease [J]. Clin ResCardiol, 2018, 107(3): 201-213.
|
| [17] |
Igarashi K, Ueda S, Yoshida K, et al. Polyamines in renal failure [J]. Amino Acids, 2006, 31(4): 477-483.
|
| [18] |
Shah VO, Townsend RR, Feldman HI, et al. Plasma metabolomic profiles in different stages of CKD [J]. Clin J Am Soc Nephrol, 2013, 8(3): 363-370.
|
| [19] |
Duranton F, Lundin U, Gayrard N, et al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function [J]. Clin J Am Soc Nephrol, 2014, 9(1): 37-45.
|
| [20] |
Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease [J]. J Am Soc Nephrol, 2013, 24(11): 1901-1912.
|
| [21] |
You YH, Quach T, Saito R, et al. Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease [J]. J Am Soc Nephrol, 2016, 27(2): 466-481.
|
| [22] |
Li M, Wang X, Aa J, et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy [J]. Am J Physiol Renal Physiol, 2013, 304(11): F1317-F1324.
|
| [23] |
Zheng L, Cardaci S, Jerby L, et al. Fumarate induces redox-dependent senescence by modifying glutathione metabolism [J]. Nat Commun, 2015, 6: 6001.
|
| [24] |
Goek ON, Doring A, Gieger C, et al. Serum metabolite concentrations and decreased GFR in the general population [J]. Am J Kidney Dis, 2012, 60(2): 197-206.
|
| [25] |
Wang F, Sun L, Sun Q, et al. Associations of plasma amino acid and acylcarnitine profiles with incident reduced glomerular filtration rate [J]. Clin J Am Soc Nephrol, 2018, 13(4): 560-568.
|
| [26] |
Afshinnia F, Rajendiran TM, Soni T, et al. Impaired beta-oxidation and altered complex lipid fatty acid partitioning with advancing CKD [J]. J Am Soc Nephrol, 2018, 29(1): 295-306.
|
| [27] |
Kim RB, Morse BL, Djurdjev O, et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events [J]. Kidney Int, 2016, 89(5): 1144-1152.
|
| [28] |
Kaysen GA, Johansen KL, Chertow GM, et al. Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis [J]. J Ren Nutr, 2015, 25(4): 351-356.
|
| [29] |
Shafi T, Powe NR, Meyer TW, et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients [J]. J Am Soc Nephrol, 2017, 28(1): 321-331.
|
| [30] |
Tariq A, Mansoor MA, Marti HP, et al. Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy [J]. Clin Biochem, 2018, 56: 33-40.
|